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This Month in the Journal
This month’s “Human Genetics ’97” series focuses on
the genetics of somatic tissues, specifically the extent and
consequences of genomic instability in the soma. It is
widely appreciated that somatic loss of heterozygosity
(LOH) can cause tumor development when a tumor-
suppressor gene is affected, but the frequency of LOH
at other loci is more difficult to observe. Tischfield (p.
995) discusses multiple genetic and epigenetic mecha-
nisms that could lead to allele-specific suppression of
gene expression in somatic cells, and he describes an
experimental system that allows these events to be stud-
ied in primary cell culture. Qian and Germino (p. 1000)
discuss polycystic kidney disease, which is associated
with LOH in the PKD1 gene, and they argue that LOH
may be a disease mechanism in many cases in which
dominant inheritance is coupled with sporadic incidence.
Writing in the series “Insights from Model Systems,”
St. John and Xu (p. 1006) discuss somatic LOH from
the perspective of Drosophila biology, where it serves as
a carefully constructed tool for genetic analysis. By in-
ducing mitotic recombination in engineered strains of
flies, developmental geneticists can identify and study fly
tumor-suppressor genes. The genes identified may be fa-
miliar as homologues of human tumor suppressors, such
as RB, or may be identified first in the fly and only later
in human cells, as with lats. In either case, they point
to an astonishing degree of conservation of the bio-
chemical pathways that regulate cell growth in animals
only distantly related to us.
MMAC1 Mutations in Early-Onset Breast Cancer, by
Tsou et al. (p. 1036)
Individuals with Cowden syndrome (CS) are subject to
numerous benign growths as well as to breast cancer
and other malignancies. One gene, MMAC1, is mutated
in CS pedigrees and in many spontaneous tumors.
MMAC1 encodes a protein phosphatase that acts in vitro
on phosphotyrosine or on phosphoserine or phospho-
threonine in target substrates; the physiological sub-
strates of MMAC1 are unknown. Tsou et al. report that
they have identified three novel mutations in this gene,
in families with early or bilateral breast cancer. However,
they found no evidence that MMAC1 mutations are
common among women who develop breast cancer at
an early age. Furthermore, Tsou et al. found no coding-
sequence mutations in 23 CS families for whom linkage
to the MMAC1 locus had never been established. On
this basis, they suggest that CS is genetically heteroge-
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neous. As other genes related to this disease are iden-
tified, a biochemical pathway may emerge by which this
protein phosphatase regulates cell growth.
Low-Penetrance Retinitis Pigmentosa, by McGee et al.
(p. 1059)
At least eight loci are associated with dominantly in-
herited retinitis pigmentosa, and two of these loci, RP9
and RP11, show incomplete penetrance. McGee et al.
have analyzed the inheritance of this condition in three
extended families that show linkage to RP11. They argue
that, where sibships show divergent phenotypes (pres-
ence or absence of disease), a modifier locus may account
for the difference. One modifier appears to be associated
with the RP11 allele derived from the parent who did
not transmit the disease allele. The authors suggest that
polymorphic alleles that lead to high expression of a
wild-type protein could suppress the effects of an oth-
erwise dominant mutant allele. Other models for inter-
allelic interaction or for second-site suppression are also
possible.
Aberrant Splicing of the Human AR, by Bru¨ggenwirth
et al. (p. 1067)
Karyotypic males with defects in the androgen-receptor
gene (AR) fail to develop normal male genitalia and
typically present either with ambiguous genitalia or as
apparently normal, but infertile, females. AR encodes a
ligand-activated transcription factor with a phosphory-
lation state that correlates with DNA binding activity.
Bru¨ggenwirth et al. report on a family with an unusual
form of androgen insensitivity, whose members have no
defect in their exonic or splice-junction sequences inAR.
Affected people in this family express an AR of nearly
normal size that fails to be maximally phosphorylated
or to bind target DNA, in vitro. The authors identified
a mutation in an intron, within a splice-acceptor se-
quence, and they characterized the altered mRNAs de-
rived from this mutant allele. The lesions in the AR
protein are subtle, but they affect its zinc finger domain,
which mediates DNA binding.
Puerto Ricans with Hermansky-Pudlak Syndrome, by
Hazelwood et al. (p. 1088)
Underlying the various symptoms of Hermansky-Pudlak
syndrome (HPS) are defects in several membrane-bound
organelles in diverse cell types: Melanosome abnormal-
ities lead to oculocutaneous albinism, a lack of dense
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bodies in platelets compromises blood coagulation, and
an accumulation of ceroid lipofuscin in lysosomes in
alveolar macrophages is associated with fibrotic lung
disease. One gene for this syndrome, HPS, has been
cloned, and common disease alleles are known, includ-
ing one 16-bp deletion that is common in Puerto Rico.
Hazelwood et al. show that two Puerto Rican individ-
uals with HPS lack this common allele. Indeed, they
appear to express wild-type HPS mRNA and, instead,
may carry a mutation at an entirely different locus. The
suggestion that HPS is genetically heterogenous is con-
sistent with the existence of at least 12 genes that cause
similar conditions in the mouse.
TRYP1 Mutations in ROCA, by Manga et al. (p. 1095)
Oculocutaneous albinism (OCA) among southern Af-
rican Blacks is distinctive in that the tyrosinase-negative
form (OCA1) is unknown, whereas other forms, such
as rufous OCA (ROCA or OCA3), are relatively com-
mon. Manga et al., by studying nine South African fam-
ilies, have now linked ROCA to the gene for tyrosinase-
related protein 1 (TRYP1). They identify two common
mutations in this gene and report that most albinos in
this group are either homozygotes or compound heter-
ozygotes for these mutations. In one family with a pig-
mentation phenotype similar to that for ROCA but with
still lighter hair, they found mutations in TRYP1 and in
the P gene, which is associated with OCA2. The authors
discuss this genetic interaction and its parallels with in-
teractions seen between mouse pigmentation genes.
De Novo Rearrangements in SMA, by Wirth et al.
(p. 1102)
Unlike dominant conditions, in which the sporadic in-
cidence rate provides a ready measure of mutation rate,
the mutation rate at recessive-disease loci is not com-
monly measured. Rather, this rate is usually derived from
incidence rates in populations believed to be at equilib-
rium. Now, Wirth et al. have identified de novo rear-
rangement rates for the spinal muscular-atrophy locus.
This locus contains two inverted, nearly identical repeats
of ∼500 kb, and biallelic loss or inactivation of the telo-
meric copy of the SMN gene in this region leads to spinal
muscular atrophy. Wirth et al. report that de novo re-
arrangements occur mostly during spermatogenesis and
are found in 7 of 340 families with this disease. The
mutation rate that they have deduced is in good agree-
ment with the rate calculated from equilibrium incidence
levels.
Linkage of Paget Disease of Bone to 18q, by Cody
et al. (p. 1117)
Cody et al. argue that two autosomal dominant bone
diseases, Paget disease of the bone and familial expansile
osteolysis (FEO), represent allelic disorders. Both con-
ditions present with bone lesions, and, in both, osteo-
clasts appear to carry viral inclusions in their cytoplasm
and nuclei, probably indicating infection by a paramyxo-
virus. FEO leads to debilitating disease in the limbs,
which may be spared in Paget disease, and it presents
at an earlier age. Cody et al. describe a family with Paget
disease in which the condition is linked to 18q, where
FEO maps. In this pedigree, a single outlier, who is symp-
tomatic but who lacks the disease haplotype, compli-
cates this argument.
Laboratory Policies for Testing of Children, by Wertz
and Reilly (p. 1163)
Wertz and Reilly have surveyed diagnostic genetic lab-
oratories to determine how they respond to requests for
two controversial kinds of testing—those that determine
a child’s predisposition to untreatable illnesses that arise
only later in life and those that determine, in a minor
too young to face reproductive decisions, carrier status
for a recessive condition. Of 105 such laboratories, a
slight majority appear to recognize a responsibility to
regulate such testing, in that they have refused—at least
once—to test a child. In addition, many labs report that
they have been contacted by physicians concerned about
the appropriateness of such tests. Wertz and Reilly note
that policy statements from groups involved with
Huntington disease have influenced policy decisions by
laboratories, and they suggest that similar statements
from other groups could help standardize testing policy
for other conditions as well.
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